—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Pacific Biosciences of California (PACB) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for PACB, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 2.08 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How PACB has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 2.08 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Pacific Biosciences of California moved 2.08% on average · correlation 0.22 · higher than 99% of US names
  • Beta, last 3 months 2.75 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.67% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +12.06% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Medical Devices · US · 8 names with week and year-to-date

Peer group

Medical Devices · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against PACB on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Pacific Biosciences of California

PACB in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Pacific Biosciences designs and sells DNA sequencing systems built around its long-read SMRT technology, alongside the reagent kits and consumables that instruments consume with each run. Its machines, including the Revio, Vega and Sequel lines, read long strands of DNA to help researchers resolve complex genetic questions that shorter-read methods struggle with. Customers include academic and government labs, hospitals, pharmaceutical firms and agricultural researchers. It is based in Menlo Park, California.
Where it sits in the stack
PacBio sits outside Closelooknet's AI build-out index; within our wider universe it belongs to the life-sciences and genomic-tools sector, grouped with sequencing platform makers rather than chip, equipment or infrastructure names.
Who it is priced against
Closelooknet has not set a formal peer group for PacBio; the market usually places it alongside Illumina and Oxford Nanopore, the other sequencing platforms competing for long-read and short-read genomic volume.
Why Closelooknet tracks it
PacBio holds no seat in Closelooknet's index and carries no Closelooknet score; the diary has not yet quoted it in any edition.
What the diary watches
The diary watches whether adoption of its newer instruments turns into steady consumable and reagent sales, which would point to recurring sequencing volume rather than one-off machine purchases.

Pacific Biosciences of California (PACB) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Pacific Biosciences of California (PACB)?

Pacific Biosciences of California trades as PACB on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is PACB in a Closelooknet index?

Not currently — Pacific Biosciences of California is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does PACB trade against its moving averages?

Recovery attempt under the 200-day: Trades +20.7% vs the 50-day and +2.8% vs the 200-day average, 40.7% below the 52-week high and +51.4% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Pacific Biosciences of California trade when bond yields rise?

Over the past year Pacific Biosciences of California had a beta of 2.08 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 99% of US names. On the 10 sessions in which long bonds fell most it moved −0.67% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Pacific Biosciences of California do?

Pacific Biosciences designs and sells DNA sequencing systems built around its long-read SMRT technology, alongside the reagent kits and consumables that instruments consume with each run. Its machines, including the Revio, Vega and Sequel lines, read long strands of DNA to help researchers resolve complex genetic questions that shorter-read methods struggle with. Customers include academic and government labs, hospitals, pharmaceutical firms and agricultural researchers. Closelooknet has not set a formal peer group for PacBio; the market usually places it alongside Illumina and Oxford Nanopore, the other sequencing platforms competing for long-read and short-read genomic volume.

Where does Pacific Biosciences of California sit in the AI build-out?

PacBio sits outside Closelooknet's AI build-out index; within our wider universe it belongs to the life-sciences and genomic-tools sector, grouped with sequencing platform makers rather than chip, equipment or infrastructure names. PacBio holds no seat in Closelooknet's index and carries no Closelooknet score; the diary has not yet quoted it in any edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for PACB, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.